Trial Profile
To compare the safety and Pharmacokinetics outcomes of subcutaneously administered Leuprolide acetate in orchiectomized, advanced prostate cancer patients with head to head study conducted in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- 03 Apr 2017 New trial record
- 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium